CLINICAL AND PARACLINICAL CHARACTERISTICS OF STAGE II–IIIA BREAST CANCER PATIENTS AT THANH HOA CANCER HOSPITAL

Le Thi Yen1,2,3, Pham Van Tam4
1 K Hospital
2 Hanoi Medical University
3 Vietnam Academy of Traditional Medicine
4 Thanh Hoa Oncology Hospital

Main Article Content

Abstract

Overview: Breast cancer (BC) is the most common cancer in women and also the leading cause of cancer-related mortality among women. However, there are differences in the clinical and paraclinical characteristics of patients across different geographical regions. We conducted a study on the clinical and paraclinical characteristics of BC patients diagnosed at Thanh Hoa Cancer Hospital to clarify the differences compared to other geographical areas.


Patients and Methods: Data were collected from the medical records of 87 patients diagnosed with stage II–IIIA BC at Thanh Hoa Cancer Hospital from February 2020 to December 2024.


Results:The mean age at diagnosis was 46.9 ± 7.6 years, primarily in the 40–59 age group (78.1%). The majority of patients detected the disease by self-palpation of a breast mass (72.4%) and presented for examination within 6 months (65.5%) of discovering the mass. The most common tumor location was the left breast (65.5%) and the upper outer quadrant (71.3%). Regarding molecular biology, the rate of positive hormone receptors (ER and/or PR) was 85.1%; HER2 negativity accounted for 62.1%, and Ki67 > 20% accounted for 70.1%. The Luminal B subtype had the highest prevalence (55.2%). Conclusion: Our study population was diagnosed with the disease at a younger age and had a longer time to treatment access compared to previously conducted studies.

Article Details

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
2. Trần Văn Thuấn. Điều Trị Nội Khoa Bệnh Ung Thư Vú. Nhà Xuất Bản y Học Hà Nội; 2019.
3. Nguyễn TT, Phạm HK. Đánh giá kết quả hóa trị bổ trợ phác đồ 4ac-4d trên bệnh nhân utv giai đoạn ii –iiia bệnh viện ung bướu thanh hóa. VMJ. 2021;508(1). doi:10.51298/vmj.v508i1.1550
4. Phạm Tuấn Anh. đánh giá hiệu quả phác đồ hoá chất 4AC – 4P liều dày trong điều trị bổ trợ ung thư vú. Luận án Tiến sỹ. Trường Đại học Y Hà Nội; 2020.
5. Martin RCG, Chagpar A, Scoggins CR, et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg. 2005;241(6):1005-1012; discussion 1012-1015. doi:10.1097/01.sla.0000165200.32722.02.
6. Tạ Văn Tờ. Nghiên Cứu Hình Thái Học, Hóa Mô Miễn Dịch và Giá Trị Tiên Lượng Của Chúng Trong Ung Thư Biểu Mô Tuyến vú. Luận Văn Tiến Sỹ Y Học. Trường Đại Học Y Hà Nội; 2004.
7. Wang RX, Chen S, Jin X, Shao ZM. Value of Ki-67 Expression in Triple-Negative Breast Cancer before and after Neoadjuvant Chemotherapy with Weekly Paclitaxel plus Carboplatin. Sci Rep. 2016;6(1):30091. - Google Search. Accessed September 29, 2025.
8. Nguyễn Thị Phương Thảo. Kết Quả Hóa Trị Bổ Trợ Trước Phác Đồ 4AC 4T ở Bệnh Nhân Ung Thư vú Giai Đoạn Tiến Triển Tại Chỗ. Luận Văn Thạc Sỹ y Học. Trường Đại Học Y Hà Nội; 2021.